FCC Approves $3.54B Nexstar-Tegna Merger, Waiving Broadcast Ownership Cap 
Iran War Fears Send Oil Prices Surging as U.S. Weighs Ground Troop Deployment 
Iran Threatens Gulf Infrastructure as U.S.-Israel War Enters Critical 48-Hour Window 
Xiaomi Shares Drop After SU7 Launch as Margin Concerns Weigh on Investors 
FEMSA Cuts Jobs at Spin Fintech Unit, Refocuses Strategy on Oxxo Stores 
Global Markets Tumble as US-Iran Tensions Escalate, Oil Surges 
Paraguay Central Bank Holds Interest Rate at 5.5% Amid Slowing Growth 
Global Markets Reel as Middle East Tensions Escalate Energy Fears 
Tesla FSD EU Approval Delayed to April 10 as RDW Completes Final Review 
Elliott Investment Management Takes Activist Stake in Align Technology 
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 
U.S. Appeals Court Strikes Down FTC Order Against TurboTax "Free" Advertising 
Israel Defies Trump's Warning, Launches New Strikes on Iran Amid Growing Global Energy Crisis 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
Dollar Weakens as Middle East War Reshapes Global Rate Expectations 
NVIDIA's Feynman AI Chip May Face Redesign Amid TSMC Capacity Crunch 
Super Micro Computer Shares Plunge After Co-Founder Charged in AI Chip Smuggling Case 
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
